Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Taro Pharm Inds (TARO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,301,126
  • Shares Outstanding, K 40,100
  • Annual Sales, $ 879,390 K
  • Annual Income, $ 456,360 K
  • 36-Month Beta 0.63
  • Price/Sales 4.89
  • Price/Cash Flow 9.22
  • Price/Book 1.97

Price Performance

See More
Period Period Low Period High Performance
1-Month
103.00 +2.01%
on 01/10/18
108.53 -3.19%
on 01/18/18
-0.85 (-0.80%)
since 12/19/17
3-Month
102.60 +2.41%
on 12/05/17
128.46 -18.21%
on 11/08/17
-2.82 (-2.61%)
since 10/19/17
52-Week
94.00 +11.78%
on 08/09/17
128.46 -18.21%
on 11/08/17
+3.73 (+3.68%)
since 01/19/17

Most Recent Stories

More News
Taro Provides Results for September 30, 2017

November 7, 2017-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the three and six months ended September 30, 2017....

TARO : 105.07 (-2.04%)
Taro to Announce Second Quarter Results on November 7, 2017

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("TARO" or the "Company") announced today that it plans to release its financial results for the quarter and six months ended September 30,...

TARO : 105.07 (-2.04%)
Taro Announces Joining of CEO

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") announced today that Mr. Uday Baldota has joined the Company as its Chief Executive Officer ("CEO") effective August...

TARO : 105.07 (-2.04%)
Featured Company News - Dr. Reddy's Laboratories Announces the Out-Licensing of DFD-06 to Encore Dermatology

Research Desk Line-up: Taro Pharma Industries Post Earnings Coverage

RDY : 38.67 (+1.02%)
TARO : 105.07 (-2.04%)
Taro Provides Results for Quarter Ended June 2017

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter ended June 30, 2017.

TARO : 105.07 (-2.04%)
Global Mouth Ulcer Market 2017-2021 - Key vendors are Blistex, Church & Dwight, Novartis Pharmaceuticals & Valeant Pharmaceuticals

Research and Markets has announced the addition of the "Global Mouth Ulcer Market 2017-2021" report to their offering. The analysts forecast the global mouth ulcer market to grow at a CAGR of 4.31% during...

HSIC : 75.96 (+1.80%)
NVS : 86.94 (+0.61%)
TARO : 105.07 (-2.04%)
Taro Annual Report on Form 20-F Available for Fiscal Year Ended March 31, 2017

Taro Pharmaceutical Industries Ltd. (NYSE:TARO, "Taro") announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2017, filed with the Securities and Exchange Commission...

TARO : 105.07 (-2.04%)
Featured Company News - DURECT-SANDOZ Collaboration Clears HSR Review; Paves Path for POSIMIR Development and Marketing in the U.S.

Research Desk Line-up: Taro Pharma Post Earnings Coverage

DRRX : 1.20 (+2.56%)
NVS : 86.94 (+0.61%)
TARO : 105.07 (-2.04%)
Taro to Announce Results for Year Ended March 31, 2017 on May 22, 2017

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the fiscal year ended March 31, 2017, on Monday, May 22, 2017.

TARO : 105.07 (-2.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Taro Pharmaceutical Industries is engaged in the production, research and development, and marketing of prescription and over-the-counter pharmaceutical products, with a focus on generic products. In addition to the production of finished dosage form drugs, they also synthesize the pharmaceutical chemicals...

See More

Key Turning Points

2nd Resistance Point 109.02
1st Resistance Point 107.05
Last Price 105.07
1st Support Level 103.70
2nd Support Level 102.32

See More

52-Week High 128.46
Fibonacci 61.8% 115.30
Fibonacci 50% 111.23
Fibonacci 38.2% 107.16
Last Price 105.07
52-Week Low 94.00

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.